Other clinical studies in melanoma patients receiving peptide-based vaccination (Melan-A/MART-1 and NY-ESO-1) have reported an enhanced DC maturation/activation and CD8 T cell activity when the vaccine was combined with low dose IFN-α [279,280]. Here, CD8A is linked to melanoma.